Filing Flows › IGC Pharma (IGC) › Q3 2026 › vs Q2 2026
IGC Pharma (IGC) Q3 2026 vs Q2 2026 (quarter over quarter)
IGC Pharma's revenue rose $63K (+24%) from $265K in Q2 2026 to $328K in Q3 2026. The biggest changes: White Labeling Services +$65K (+25%); Wellness and Lifestyle −$2K (-22%).
IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%, net loss $2.0M, operating cash flow −$1.4M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| White Labeling Services | $321K | $256K | $65K | +25% |
| Wellness and Lifestyle | $7K | $9K | −$2K | -22% |
| Revenue | $328K | $265K | $63K | +24% |
| Net loss | $2.0M | $2.9M | −$890K | -30% |
| Costs & expenses | $2.4M | $3.2M | −$827K | -26% |
| Operating costs | $2.3M | $3.0M | −$790K | -26% |
| Interest & other, net | $115K | $152K | −$37K | -24% |
| Cost of revenue | $267K | $217K | $50K | +23% |
| Research & development | $1.0M | $1.4M | −$377K | -27% |
| SG&A | $979K | $1.4M | −$463K | -32% |
| Operating cash sources | $2.0M | $2.7M | −$690K | -25% |
| Depreciation & amortization | $58K | $56K | $2K | +4% |
| Working capital & other | $571K | $1.3M | −$759K | -57% |
| Cash used in operations | $1.4M | $1.4M | $67K | +5% |
| Net loss absorbed | $2.0M | $2.9M | −$890K | -30% |
Questions
How much did IGC Pharma's revenue grow quarter over quarter in Q3 2026?
IGC Pharma's revenue rose $63K (+24%) from $265K in Q2 2026 to $328K in Q3 2026.
What drove IGC Pharma's revenue change in Q3 2026?
White Labeling Services +$65K (+25%); Wellness and Lifestyle −$2K (-22%).